Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for
Qi Hao1, Wenzhe Zhao1, Zhijia Li1
1Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
Abstract:
Cyclin-dependent kinases (CDKs) are pivotal regulators of the cell cycle and transcriptional machinery, making them attractive targets for cancer therapy. While CDK inhibitors have demonstrated promising clinical outcomes, they also face challenges in enhancing efficacy, particularly in overcoming drug resistance. Combination therapies have emerged as a key strategy to augment the effectiveness of CDK inhibitors when used alongside other kinase inhibitors or non-kinase-targeted agents. Dual-target inhibitors that simultaneously inhibit CDKs and other oncogenic drivers are gaining attention, offering novel avenues to optimize cancer therapy. Based on the structural characterization and biological functions of CDKs, this review comprehensively examines the structure-activity relationship (SAR) of existing dual-target CDK inhibitors from a drug design perspective. We also thoroughly investigate the preclinical studies and clinical translational potential of combination therapies and dual-target inhibitors. Tailoring CDK inhibitors to specific cancer subtypes and therapeutic settings will inspire innovative approaches for the next generation of CDK-related therapies, ultimately improving patient survival.
Insights
This review explores dual-target cyclin-dependent kinase (CDK) inhibitors and combination therapies for cancer treatment. It highlights strategies to improve CDK inhibitor efficacy and overcome drug resistance for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation and are key targets in cancer therapy.
- Current CDK inhibitors show promise but face challenges with drug resistance and limited efficacy.
- Combination therapies and dual-target inhibitors offer new strategies to enhance anti-cancer effects.
Purpose of the Study:
- To review the structure-activity relationship (SAR) of dual-target CDK inhibitors.
- To examine preclinical and clinical data on combination therapies and dual-target CDK inhibitors.
- To discuss future directions for developing next-generation CDK-based cancer treatments.
Main Methods:
- Comprehensive literature review of existing dual-target CDK inhibitors.
- Analysis of structure-activity relationships based on CDK structural and functional data.
- Evaluation of preclinical studies and clinical trial data for combination therapies and dual-target agents.
Main Results:
- Dual-target inhibitors present a promising approach to overcome resistance and improve efficacy.
- Combination therapies involving CDK inhibitors show potential for enhanced anti-cancer activity.
- SAR analysis provides insights for rational drug design of novel CDK inhibitors.
Conclusions:
- Optimizing CDK inhibitors through dual-targeting and combination strategies is crucial for advancing cancer therapy.
- Tailoring treatments to specific cancer subtypes will improve the effectiveness of CDK inhibitors.
- Further research into dual-target inhibitors and combination therapies holds potential for improved patient survival.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:44Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers